SAMHSA extends methadone take-home flexibilities initiated during pandemic
The Substance Abuse and Mental Health Services Administration yesterday extended certain methadone take-home flexibilities for opioid treatment programs until one year after the end of the COVID-19 public health emergency, and said it is considering ways to make the flexibilities permanent.
SAMHSA in 2020 allowed states to request a blanket exception to allow stable patients in an opioid treatment program to receive 28 days of take-home doses of their OUD medication, and other eligible patients to receive up to 14 days of take-home medication, which the agency said has enhanced and encouraged use of treatment services.
Related News Articles
Headline
The Centers for Disease Control and Prevention Aug. 5 announced a new campaign educating youth ages 12-17 on substance use, mental health and how they are…
Headline
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…
Headline
The AHA released a new toolkit to improve continuity of care for patients with opioid and stimulant use disorders. Developed with support from the Centers for…
Headline
The Substance Abuse and Mental Health Services Administration July 28 released its latest national survey on drug use and mental health. Among the findings,…
Headline
The U.S. Department of Health and Human Services July 10 rescinded a policy that extended certain federal public benefits to immigrants lacking permanent legal…
Headline
The House June 4 passed the AHA-supported SUPPORT Act (H.R. 2483) by a 366-57 vote. The legislation reauthorizes key prevention, treatment and recovery…